Cargando…
Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway
Humoral immunity to factor VIII (FVIII) represents a significant challenge for the treatment of patients with hemophilia A. Current paradigms indicate that neutralizing antibodies against FVIII (inhibitors) occur through a classical CD4 T cell, germinal center (GC) dependent process. However, clinic...
Autores principales: | Patel, Seema R., Lundgren, Taran S., Baldwin, Wallace Hunter, Cox, Courtney, Parker, Ernest T., Healey, John F., Jajosky, Ryan P., Zerra, Patricia E., Josephson, Cassandra D., Doering, Christopher B., Stowell, Sean R., Meeks, Shannon L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132091/ https://www.ncbi.nlm.nih.gov/pubmed/35634288 http://dx.doi.org/10.3389/fimmu.2022.880829 |
Ejemplares similares
-
Engineering a Therapeutic Protein to Enhance the Study of Anti-Drug Immunity
por: Zerra, Patricia E., et al.
Publicado: (2022) -
Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation
por: Zerra, Patricia E., et al.
Publicado: (2020) -
The Immune Response to the fVIII Gene Therapy in Preclinical Models
por: Patel, Seema R., et al.
Publicado: (2020) -
Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice
por: Lundgren, Taran S., et al.
Publicado: (2022) -
Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner
por: Batsuli, Glaivy, et al.
Publicado: (2023)